Hims and Hers Ends Weight Loss Sales
This is a news story, published by Insider, that relates primarily to Novo Nordisk's news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsInsider news
For more news from Insider, you can click here:
more news from InsiderAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
FDA announcement. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss drugs news, semaglutide drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
FDA updateInsider
•Health
Health
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
78% Informative
Hims and Hers' stock fell over 19% in after-hours trading on Monday .
The telehealth company has been making legal copies of Novo Nordisk's weight loss and diabetes drugs.
The FDA removed semaglutide injections from its shortage list last week .
Hims ' GLP-1 drugs start at $ 199 a month, while Wegovy and Ozempic cost over $ 900 a month.
Small business owner?